Thomas J M, Verbanac K M, Smith J P, Kasten-Jolly J, Gross U, Rebellato L M, Haisch C E, Carver F M, Thomas F T
Department of Surgery, University Medical Center of Eastern North Carolina, Greenville 27834.
Transplantation. 1995 Jan 27;59(2):245-55.
Infusion of donor bone marrow cells (DBMC), a long-standing, successful strategy for inducing tolerance in experimental rodent transplantation models, can promote long-term acceptance of life-sustaining renal allografts in rhesus monkeys with no maintenance immunosuppression. To investigate the immunological basis for heterogeneity in duration of long-term graft acceptance following infusion of the DR-/dim fraction of DBMC into RATG-treated rhesus monkeys, we examined the relationship of recipient-donor major histo-compatibility class I and II DR matching to the development of antidonor antibody-dependent cellular cytotoxicity (ADCC) and renal allograft survival. The findings indicate a requirement for sharing one DR allele to achieve long-term graft acceptance. The observed immunological consequence of DR sharing that correlated with functional graft tolerance in this model was the suppression of early antidonor ADCC+ IgG antibody responses. Significant associations were observed between graft survival and suppression of ADCC antibody (P < 0.0005), graft survival and DR sharing (P < 0.005), and DR sharing and suppression of ADCC (P < 0.02). Early antidonor ADCC antibody responses associated with failure to maintain graft tolerance and were most consistently directed to donor class I. The required one DR antigen sharing in DBMC-induced suppression of antidonor class I antibody suggests a restriction for recipient DR, implying critical regulation of a response to donor antigen presented on recipient cells. We hypothesize a DBMC tolerogenic mechanism in which presentation of donor class I peptide by a shared DR allele configuration allows a veto effect by DBMC. Thus DR sharing would allow DBMC veto cells to reduce clonal expansion elicited by both the direct and indirect antigen presentation pathways.
输注供体骨髓细胞(DBMC)是在实验性啮齿动物移植模型中诱导免疫耐受的一种长期且成功的策略,它可以促进恒河猴长期接受维持生命的肾移植,且无需维持免疫抑制。为了研究在经大鼠抗胸腺细胞球蛋白(RATG)处理的恒河猴中输注DBMC的DR - /暗亚群后长期移植接受持续时间异质性的免疫基础,我们研究了受体 - 供体主要组织相容性复合体I类和II类DR匹配与抗供体抗体依赖性细胞毒性(ADCC)的发展及肾移植存活之间的关系。研究结果表明,需要共享一个DR等位基因才能实现长期移植接受。在该模型中,观察到的与功能性移植耐受相关的DR共享的免疫后果是早期抗供体ADCC + IgG抗体反应受到抑制。在移植存活与ADCC抗体抑制之间(P < 0.0005)、移植存活与DR共享之间(P < 0.005)以及DR共享与ADCC抑制之间(P < 0.02)观察到显著相关性。与无法维持移植耐受相关的早期抗供体ADCC抗体反应最一致地针对供体I类。DBMC诱导的抗供体I类抗体抑制中所需的一个DR抗原共享表明对受体DR有一定限制,这意味着对受体细胞上呈递的供体抗原反应的关键调节。我们推测一种DBMC致耐受机制,即通过共享DR等位基因构型呈递供体I类肽允许DBMC产生否决效应。因此,DR共享将允许DBMC否决细胞减少由直接和间接抗原呈递途径引发的克隆扩增。